Sanofi-Regeneron's Dupixent wins FDA's nod for 'smoker's lung'
Adds details on Dupixent in paragraphs 2 and 4, analyst estimates in paragraph 5, trial details in paragraph 8
By Sriparna Roy
Sept 27 (Reuters) -The U.S. Food and Drug Administration has approved Sanofi SASY.PA and Regeneron's REGN.O blockbuster drug Dupixent for patients with a chronic lung disease, commonly known as "smoker's lung", the companies said on Friday.
The health regulator has cleared the drug's use as an add-on treatment for some adults with inadequately controlled chronic obstructive pulmonary disease (COPD), a condition that progressively damages the lungs and causes restricted airflow.
Sanofi last year recorded a combined 10.72 billion euros ($11.94 billion) in sales for Dupixent, which is already used to treat immune system-related conditions such as asthma and eczema in the U.S. and other countries.
The company has said it expects the target COPD patient population eligible for the drug to be roughly 300,000 patients in the U.S. It has anticipated steeper growth in Dupixent sales in 2025 after the launch for COPD in the country.
Analysts on average expect Dupixent, by far Sanofi's best-selling drug, to generate more than 21 billion euros in revenue in 2030, according to estimates compiled by LSEG. BMO Capital Markets analyst Evan Seigerman in May estimated the drug's peak sales in COPD to reach $2.9 billion in the same year.
COPD, which is the fourth leading cause of death globally, is a lifelong condition that commonly affects cigarette smokers but can also be caused by air pollution and related occupational hazards.
In July, the European Union approved the use of the drug in patients who cannot be helped by standard inhaled treatments for the potentially deadly disease.
In late-stage trials, the drug significantly reduced the moderate or severe exacerbations and also helped to significantly improve lung function, compared to a placebo.
Shares of Regeneron were trading 2.5% higher in morning trade.
Reporting by Sriparna Roy in Bengaluru; Editing by Shilpi Majumdar and Sriraj Kalluvila
免责声明: XM Group仅提供在线交易平台的执行服务和访问权限，并允许个人查看和/或使用网站或网站所提供的内容，但无意进行任何更改或扩展，也不会更改或扩展其服务和访问权限。所有访问和使用权限，将受下列条款与条例约束：(i) 条款与条例；(ii) 风险提示；以及(iii) 完整免责声明。请注意，网站所提供的所有讯息，仅限一般资讯用途。此外，XM所有在线交易平台的内容并不构成，也不能被用于任何未经授权的金融市场交易邀约和/或邀请。金融市场交易对于您的投资资本含有重大风险。
所有在线交易平台所发布的资料，仅适用于教育/资讯类用途，不包含也不应被视为用于金融、投资税或交易相关咨询和建议，或是交易价格纪录，或是任何金融商品或非应邀途径的金融相关优惠的交易邀约或邀请。
本网站上由XM和第三方供应商所提供的所有内容，包括意见、新闻、研究、分析、价格、其他资讯和第三方网站链接，皆保持不变，并作为一般市场评论所提供，而非投资性建议。所有在线交易平台所发布的资料，仅适用于教育/资讯类用途，不包含也不应被视为适用于金融、投资税或交易相关咨询和建议，或是交易价格纪录，或是任何金融商品或非应邀途径的金融相关优惠的交易邀约或邀请。请确保您已阅读并完全理解，XM非独立投资研究提示和风险提示相关资讯，更多详情请点击 这里。
